Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: Results from the VA HCV-001 study

Digestive Diseases and Sciences

Volumn 53, Issue 3, 2008, Pages 809-814

  Tsui, Judith I ^a   Currie, Sue ^a   Shen, Hui ^b   Bini, Edmund J ^c   Brau, Norbert ^c   Wright, Teresa L ^d  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Roche Molecular Diagnostics   (United States)

Author keywords

Elderly; Hepatitis C Virus

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; AGING; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; COMORBIDITY; CONFOUNDING VARIABLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING; UNSPECIFIED SIDE EFFECT; VETERAN; VIROLOGY;

AGE FACTORS; ANTIVIRAL AGENTS; FEMALE; HEALTHCARE DISPARITIES; HEPATITIS C, CHRONIC; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 39849100679     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9926-x     Document Type: Article

References (17)

1. Armstrong GL, Wasley A, Simard EP et al (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705-714
2. NIH Consensus Statement on Management of Hepatitis C: (2002) NIH Consens State Sci Statements 19:1-46
3. Strader DB, Wright T, Thomas DL et al (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171
4. Marcellin P, Asselah T, Boyer N (2002) Fibrosis and disease progression in hepatitis C. Hepatology 36:S47-S56
5. Poynard T, Ratziu V, Benmanov Y et al (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20:47-55
6. Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36:S35-S46
7. Regev A, Schiff ER (2001) Liver disease in the elderly. Gastroenterol Clin North Am 30:547-63, x-xi
8. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750
9. Bini EJ, Brau N, Currie S et al (2005) Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 100:1772-1779
10. Brau N, Bini EJ, Currie S et al (2006) Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 13:242-249
11. VA Centers of Excellence in Hepatitis C Research and Education. VA Treatment Recommendations for Patients with Chronic Hepatitis C: version 1.2. 2-25-1999
12. Horiike N, Masumoto T, Nakanishi K et al (1995) Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 10:246-249
13. Koyama R, Arase Y, Ikeda K et al (2006) Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 49:121-126
14. Van Thiel DH, Friedlander L, Caraceni P, Molloy PJ, Kania RJ (1995) Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci 50:M330-M333
15. Thabut D, Le Calvez S, Thibault V et al (2006) Hepatitis C in 6,865 patients 65 year or older: a severe and neglected curable disease? Am J Gastroenterol 101:1260-1267
16. Nudo C, Gupta S, Alpert E et al Elderly patients are at greater risk for cytopenia during anitviral therapy for hepatitis C. CDDW 2004 abstract, accessed at: http://www.cagacg.org/cddw/cddw2004/abs/abs048.htm
17. Walter LC, Covinsky KE (2001) Cancer screening in elderly patients: a framework for individualized decision making. Jama 285:2750-2756